Whole-genome analysis of papillary kidney cancer finds significant noncoding alterations

To date, studies on papillary renal-cell carcinoma (pRCC) have largely focused on coding alterations in traditional drivers, particularly the tyrosine-kinase, Met. However, for a significant fraction of tumors, researchers have been unable to determine a clear molecular etiology. To address this, we perform the first whole-genome analysis of pRCC. Elaborating on previous results on MET, we find a germline SNP (rs11762213) in this gene predicting prognosis. Surprisingly, we detect no enrichment for small structural variants disrupting MET. Next, we scrutinize noncoding mutations, discovering potentially impactful ones associated with MET. Many of these are in an intron connected to a known, oncogenic alternative-splicing event; moreover, we find methylation dysregulation nearby, leading to a cryptic promoter activation. We also notice an elevation of mutations in the long noncoding RNA NEAT1, and these mutations are associated with increased expression and unfavorable outcome. Finally, to address the origin of pRCC heterogeneity, we carry out whole-genome analyses of mutational processes. First, we investigate genome-wide mutational patterns, finding they are governed mostly by methylation-associated C-to-T transitions. We also observe significantly more mutations in open chromatin and early-replicating regions in tumors with chromatin-modifier alterations. Finally, we reconstruct cancer-evolutionary trees, which have markedly different topologies and suggested evolutionary trajectories for the different subtypes of pRCC.

[1]  Rajvir Dahiya,et al.  Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. , 2015, Cancer research.

[2]  P. Hanawalt,et al.  Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair , 2016, Cell.

[3]  P. Choyke,et al.  Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.

[4]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[5]  Jing Zhang,et al.  The real cost of sequencing: scaling computation to keep pace with data generation , 2016, Genome biology.

[6]  F. Lyko,et al.  Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription , 2010, Oncogene.

[7]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[8]  Gabor T. Marth,et al.  Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics , 2013, Science.

[9]  Ben Lehner,et al.  Differential DNA mismatch repair underlies mutation rate variation across the human genome , 2015, Nature.

[10]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[11]  Martin Renqiang Min,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[12]  Michael B Atkins,et al.  Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. , 2013, The Lancet. Oncology.

[13]  Jianyong Zheng,et al.  NEAT expression is associated with tumor recurrence and unfavorable prognosis in colorectal cancer , 2015, Oncotarget.

[14]  C. Tyler-Smith,et al.  Ancient DNA and the rewriting of human history: be sparing with Occam’s razor , 2016, Genome Biology.

[15]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[16]  W. Samlowski,et al.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Lawrence A. Donehower,et al.  The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.

[18]  Gang Chen,et al.  Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients. , 2015, International journal of clinical and experimental pathology.

[19]  S. Henderson,et al.  APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.

[20]  A. Jacobsen,et al.  Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma , 2016, Cancer.

[21]  T. Waters,et al.  Thymine-DNA glycosylase and G to A transition mutations at CpG sites. , 2000, Mutation research.

[22]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[23]  Antonio Lopez-Beltran,et al.  Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.

[24]  Thomas Zichner,et al.  DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..

[25]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[26]  Ryan M. Layer,et al.  LUMPY: a probabilistic framework for structural variant discovery , 2012, Genome Biology.

[27]  Dan Wang,et al.  IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data , 2012, Bioinform..

[28]  B. Jiang,et al.  Aberrant NEAT1 expression is associated with clinical outcome in high grade glioma patients , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  Chris Sander,et al.  An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.

[30]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[31]  F Buffa,et al.  Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival , 2014, Oncogene.

[32]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[33]  William Stafford Noble,et al.  Identification of higher-order functional domains in the human ENCODE regions. , 2007, Genome research.

[34]  Serena Nik-Zainal,et al.  A mutational signature in gastric cancer suggests therapeutic strategies , 2015, Nature Communications.

[35]  Hshin-Ping Wu,et al.  Genome-wide analysis of light-regulated alternative splicing mediated by photoreceptors in Physcomitrella patens , 2014, Genome Biology.

[36]  Eugenia G. Giannopoulou,et al.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer , 2014, Nature Communications.

[37]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[38]  D. Mager,et al.  Endogenous retroviral promoter exaptation in human cancer , 2016, Mobile DNA.

[39]  J. Feliu,et al.  Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis , 2013, Gut.

[40]  Kevin Y. Yip,et al.  FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer , 2014, Genome Biology.

[41]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[42]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[43]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[44]  Michael O Dorschner,et al.  Sequencing newly replicated DNA reveals widespread plasticity in human replication timing , 2009, Proceedings of the National Academy of Sciences.

[45]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[46]  Shankar Vembu,et al.  PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors , 2015, Genome Biology.

[47]  Chris Sander,et al.  Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. , 2016, Cell reports.

[48]  W. Linehan,et al.  Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. , 2012, The Journal of urology.

[49]  Mingming Jia,et al.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..

[50]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[51]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[52]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[53]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[54]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.